EGFR and cancer: The anti-cancer effects of saracatinib were mediated through inhibition of p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated protein kinase (ERK), or epidermal growth factor receptor (EGFR) signaling pathways.